Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effect of E-OA-07 on Acute Pain Response in Subjects Suffering From Knee OA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory adults of either sex aged 40 to 60 years.~* Subjects with moderate OA of the knee, which can be clinically, categorized as ARA functional Class II and III with radiological confirmation of Kellgren Lawrence Grade II and III. (incase of bilateral OA, the knee with the more severe symptoms will be defined as index joint)~* Subjects with OA in a flare state at the baseline defined by one of following category of flare:~In subjects who have been receiving non steroidal anti-inflammatory drugs (NSAIDs) or analgesic therapy for their OA, flare will be defined as having at least two of the following three criteria while comparing screening to baseline:~1. Subject's assessment of arthritis pain VAS walking on a flat surface at baseline of ≥ 40 mm;~2. Increase of ≥ 1 grade in the patients global assessment of arthritis;~3. Increase of ≥ 1 grade in the physician's global assessment of arthritis;~In subjects who are not receiving NSAID or analgesic therapy , an OA flare state will be defined as having at least two of the following three criteria~1. Subject's assessment of arthritis pain VAS walking on a flat surface at baseline of ≥ 40 mm~2. Patient's global assessment of arthritis of ''poor''; very poor~3. Physician's global assessment of arthritis of ''poor''; very poor~Exclusion Criteria:~* Subjects with any form of arthritis other than osteoarthritis.~* Administration of intra-articular or oral steroids in the past 3 month or intra articular hyaluronic acid in the last 9 months or parenteral use of NSAIDs~* History of major chronic hepatic, cardiovascular, neurological or immunosuppressive conditions or the presence of any infections~* Subjects with localized trauma to the lower limb~* Had received oral, intramuscular, or intra-articular corticosteroids within 8 weeks, or intra-articular hyaluronic acid in the index joint within 6 months of study drug administration;~* Subjects on nutritional supplement or herbal product since last one month~* Subjects otherwise judged by the investigator to be inappropriate for inclusion in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- E-OA-07 (Lanconone) (Type: EXPERIMENTAL): 500 mg two capsules to be taken stat at the site
- Ibuprofen (Type: ACTIVE_COMPARATOR): 200 mg two capsule to be taken stat at the site

Based on this trial design, predict the completion outcome and termination type (if applicable).